Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9HCE5

UPID:
MET14_HUMAN

ALTERNATIVE NAMES:
Methyltransferase-like protein 14

ALTERNATIVE UPACC:
Q9HCE5; A6NIG1; Q969V2

BACKGROUND:
The METTL3-METTL14 complex, with Methyltransferase-like protein 14 as a non-catalytic subunit, is essential for N6-methyladenosine (m6A) modification of mRNA. This modification influences mRNA stability, affecting key processes like spermatogenesis and pluripotency in embryonic stem cells. METTL14's role in RNA binding and substrate recognition is critical for these methylation activities.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Methyltransferase-like protein 14 offers a pathway to novel therapeutic approaches. Given its critical role in mRNA methylation and impact on cell differentiation and fertility, targeting METTL14 could lead to breakthroughs in treating infertility and advancing stem cell therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.